• An elevated BST based upon genotype is a highly sensitive and specific screening test for indolent SM.

  • Standardization of screening and diagnostic testing improves SM diagnosis and KIT p.D816V detection rates.

Abstract

Timely diagnosis of systemic mastocytosis (SM) remains challenging because of care heterogeneity. We implemented a standardized approach for SM screening and diagnosis using a novel health care system–wide international screening registry. A retrospective analysis assessed rates of SM, cutaneous mastocytosis (CM), and molecular diagnoses before and 2 years after care standardization. The accuracy of individual and combined SM screening tests, basal serum tryptase (BST) ≥11.5 and ≥20.0 ng/mL, REMA ≥2, monomorphic maculopapular CM (MPCM), and elevated BST based upon tryptase genotype, was analyzed. Tryptase genotyping and high-sensitivity KIT p.D816V testing increased substantially 2 years after care standardization. SM diagnoses doubled from 47 to 94, and KIT p.D816V molecular diagnoses increased from 24 to 79. Mean BST and KIT p.D816V variant allele frequency values were significantly lower in patients diagnosed after standardization. Hereditary-alpha tryptasemia prevalence was increased in SM before care standardization (4/30 [13.3%]) but reflected the general population prevalence 2 years later at (5/76 [6.6%]). Elevated BST based upon genotype and BST ≥11.5 ng/mL had the highest sensitivities at 84.2% and 88.3%, respectively. The presence of monomorphic MPCM, elevated BST based upon tryptase genotype, and the combination of REMA ≥2 with elevated BST based upon tryptase genotype had specificities >90%. BST >20.0 ng/mL had low sensitivity and specificity and was not required to establish any indolent SM (ISM) diagnosis. Care standardization increased SM diagnosis rates, particularly in patients with low BSTs. Stratifying BST based upon genotype had the best overall sensitivity and specificity of any ISM screening test and improved the REMA score specificity.

1.
Swerdlow
SH
,
Campo
E
,
Harris
NL
, et al
. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Revised 4th ed.
World Health Organization
;
2017
.
2.
Arber
DA
,
Orazi
A
,
Hasserjian
RP
, et al
.
International Consensus Classification of myeloid neoplasms and acute leukemias: integrating morphologic, clinical, and genomic data
.
Blood
.
2022
;
140
(
11
):
1200
-
1228
.
3.
Hartmann
K
,
Escribano
L
,
Grattan
C
, et al
.
Cutaneous manifestations in patients with mastocytosis: consensus report of the European Competence Network on Mastocytosis; the American Academy of Allergy, Asthma & Immunology; and the European Academy of Allergology and Clinical Immunology
.
J Allergy Clin Immunol
.
2016
;
137
(
1
):
35
-
45
.
4.
Cohen
SS
,
Skovbo
S
,
Vestergaard
H
, et al
.
Epidemiology of systemic mastocytosis in Denmark
.
Br J Haematol
.
2014
;
166
(
4
):
521
-
528
.
5.
Schuler
CF
,
Volertas
S
,
Khokhar
D
, et al
.
Prevalence of mastocytosis and hymenoptera venom allergy in the United States
.
J Allergy Clin Immunol
.
2021
;
148
(
5
):
1316
-
1323
.
6.
Zanotti
R
,
Bonifacio
M
,
Isolan
C
, et al
.
A multidisciplinary diagnostic approach reveals a higher prevalence of indolent systemic mastocytosis: 15-years’ experience of the GISM network
.
Cancers
.
2021
;
13
(
24
):
6380
.
7.
Nagata
H
,
Worobec
AS
,
Oh
CK
, et al
.
Identification of a point mutation in the catalytic domain of the protooncogene c-kit in peripheral blood mononuclear cells of patients who have mastocytosis with an associated hematologic disorder
.
Proc Natl Acad Sci U S A
.
1995
;
92
(
23
):
10560
-
10564
.
8.
Garcia-Montero
AC
,
Jara-Acevedo
M
,
Teodosio
C
, et al
.
KIT mutation in mast cells and other bone marrow hematopoietic cell lineages in systemic mast cell disorders: a prospective study of the Spanish Network on Mastocytosis (REMA) in a series of 113 patients
.
Blood
.
2006
;
108
(
7
):
2366
-
2372
.
9.
Lim
K-H
,
Tefferi
A
,
Lasho
TL
, et al
.
Systemic mastocytosis in 342 consecutive adults: survival studies and prognostic factors
.
Blood
.
2009
;
113
(
23
):
5727
-
5736
.
10.
Escribano
L
,
Alvarez-Twose
I
,
Sanchez-Munoz
L
, et al
.
Prognosis in adult indolent systemic mastocytosis: a long-term study of the Spanish Network on Mastocytosis in a series of 145 patients
.
J Allergy Clin Immunol
.
2009
;
124
(
3
):
514
-
521
.
11.
Brockow
K
,
Jofer
C
,
Behrendt
H
,
Ring
J
.
Anaphylaxis in patients with mastocytosis: a study on history, clinical features and risk factors in 120 patients
.
Allergy
.
2008
;
63
(
2
):
226
-
232
.
12.
Oude Elberink
JN
,
de Monchy
JG
,
Kors
JW
,
van Doormaal
JJ
,
Dubois
AE
.
Fatal anaphylaxis after a yellow jacket sting, despite venom immunotherapy, in two patients with mastocytosis
.
J Allergy Clin Immunol
.
1997
;
99
(
1 Pt 1
):
153
-
154
.
13.
van der Veer
E
,
van der Goot
W
,
de Monchy
JGR
,
Kluin-Nelemans
HC
,
van Doormaal
JJ
.
High prevalence of fractures and osteoporosis in patients with indolent systemic mastocytosis
.
Allergy
.
2012
;
67
(
3
):
431
-
438
.
14.
Makovoz
A
,
Wang
J
,
Oshegbo
G
, et al
.
Assessment of osteoporosis and fracture risk in mastocytosis within a North American cohort
.
J Allergy Clin Immunol Pract
.
2021
;
9
(
12
):
4459
-
4467.e10
.
15.
Degboé
Y
,
Eischen
M
,
Nigon
D
, et al
.
Prevalence and risk factors for fragility fracture in systemic mastocytosis
.
Bone
.
2017
;
105
:
219
-
225
.
16.
Sagher
F
,
Cohen
C
,
Schorr
S
.
Concomitant bone changes in urticaria pigmentosa
.
J Invest Dermatol
.
1952
;
18
(
6
):
425
-
432
.
17.
Onnes
MC
,
van Doormaal
JJ
,
van der Veer
E
,
Versluijs
JB
,
Arends
S
,
Oude Elberink
HNG
.
Fracture risk reduction by bisphosphonates in mastocytosis?
.
J Allergy Clin Immunol Pract
.
2020
;
8
(
10
):
3557
-
3564
.
18.
Jennings
S
,
Russell
N
,
Jennings
B
, et al
.
The Mastocytosis Society survey on mast cell disorders: patient experiences and perceptions
.
J Allergy Clin Immunol Pract
.
2014
;
2
(
1
):
70
-
76
.
19.
van Anrooij
B
,
Kluin-Nelemans
JC
,
Safy
M
,
Flokstra-de Blok
BMJ
,
Oude Elberink
JNG
.
Patient-reported disease-specific quality-of-life and symptom severity in systemic mastocytosis
.
Allergy
.
2016
;
71
(
11
):
1585
-
1593
.
20.
Pyatilova
P
,
Akin
C
,
Alvarez-Twose
I
, et al
.
Refined treatment response criteria for indolent systemic mastocytosis proposed by the ECNM-AIM Consortium
.
J Allergy Clin Immunol Pract
.
2022
;
10
(
8
):
2015
-
2024
.
21.
DeAngelo
DJ
,
Radia
DH
,
George
TI
, et al
.
Safety and efficacy of avapritinib in advanced systemic mastocytosis: the phase 1 EXPLORER trial
.
Nat Med
.
2021
;
27
(
12
):
2183
-
2191
.
22.
Gotlib
J
,
Reiter
A
,
Radia
DH
, et al
.
Efficacy and safety of avapritinib in advanced systemic mastocytosis: interim analysis of the phase 2 PATHFINDER trial
.
Nat Med
.
2021
;
27
(
12
):
2192
-
2199
.
23.
Gotlib
J
,
Castells
M
,
Elberink
HO
, et al
.
Avapritinib versus placebo in indolent systemic mastocytosis
.
NEJM Evid
.
2023
;
2
(
6
):
EVIDoa2200339
.
24.
Akin
C
,
Arock
M
,
Valent
P
.
Tyrosine kinase inhibitors for the treatment of indolent systemic mastocytosis: are we there yet?
.
J Allergy Clin Immunol
.
2022
;
149
(
6
):
1912
-
1918
.
25.
Berezowska
S
,
Flaig
MJ
,
Ruëff
F
, et al
.
Adult-onset mastocytosis in the skin is highly suggestive of systemic mastocytosis
.
Mod Pathol
.
2014
;
27
(
1
):
19
-
29
.
26.
Carter
MC
,
Bai
Y
,
Ruiz-Esteves
KN
, et al
.
Detection of KIT D816V in peripheral blood of children with manifestations of cutaneous mastocytosis suggests systemic disease
.
Br J Haematol
.
2018
;
183
(
5
):
775
-
782
.
27.
Alvarez-Twose
I
,
González de Olano
D
,
Sánchez-Muñoz
L
, et al
.
Clinical, biological, and molecular characteristics of clonal mast cell disorders presenting with systemic mast cell activation symptoms
.
J Allergy Clin Immunol
.
2010
;
125
(
6
):
1269
-
1278.e2
.
28.
Carter
MC
,
Desai
A
,
Komarow
HD
, et al
.
A distinct biomolecular profile identifies monoclonal mast cell disorders in patients with idiopathic anaphylaxis
.
J Allergy Clin Immunol
.
2018
;
141
(
1
):
180
-
188.e3
.
29.
Sotlar
K
,
Horny
H-P
,
Simonitsch
I
, et al
.
CD25 indicates the neoplastic phenotype of mast cells: a novel immunohistochemical marker for the diagnosis of systemic mastocytosis (SM) in routinely processed bone marrow biopsy specimens
.
Am J Surg Pathol
.
2004
;
28
(
10
):
1319
-
1325
.
30.
Waters
AM
,
Park
HJ
,
Weskamp
AL
, et al
.
Elevated basal serum tryptase: disease distribution and variability in a regional health system
.
J Allergy Clin Immunol Pract
.
2022
;
10
(
9
):
2424
-
2435.e5
.
31.
Chovanec
J
,
Tunc
I
,
Hughes
J
, et al
.
Genetically defined individual reference ranges for tryptase limit unnecessary procedures and unmask myeloid neoplasms
.
Blood Adv
.
2023
;
7
(
9
):
1796
-
1810
.
32.
Trizuljak
J
,
Sperr
WR
,
Nekvindová
L
, et al
.
Clinical features and survival of patients with indolent systemic mastocytosis defined by the updated WHO classification
.
Allergy
.
2020
;
75
(
8
):
1927
-
1938
.
33.
Boggs
NA
,
Sun
X
,
Lyons
JJ
, et al
.
Challenges in applying diagnostic criteria for systemic mastocytosis
.
Blood Adv
.
2023
;
7
(
13
):
3150
-
3154
.
34.
Selb
J
,
Rijavec
M
,
Erzen
R
, et al
.
Routine KIT p.D816V screening identifies clonal mast cell disease in patients with hymenoptera allergy regularly missed using baseline tryptase levels alone
.
J Allergy Clin Immunol
.
2021
;
148
(
2
):
621
-
626.e7
.
35.
Jawhar
M
,
Schwaab
J
,
Horny
HP
, et al
.
Impact of centralized evaluation of bone marrow histology in systemic mastocytosis
.
Eur J Clin Invest
.
2016
;
46
(
5
):
392
-
397
.
36.
Lyons
JJ
,
Greiner
G
,
Hoermann
G
,
Metcalfe
DD
.
Incorporating tryptase genotyping into the workup and diagnosis of mast cell diseases and reactions
.
J Allergy Clin Immunol Pract
.
2022
;
10
(
8
):
1964
-
1973
.
37.
Jennings
SV
,
Slee
VM
,
Zack
RM
, et al
.
Patient perceptions in mast cell disorders
.
Immunol Allergy Clin North Am
.
2018
;
38
(
3
):
505
-
525
.
38.
Mesa
RA
,
Sullivan
EM
,
Dubinski
D
, et al
.
Patient-reported outcomes among patients with systemic mastocytosis in routine clinical practice: results of the TouchStone SM patient survey
.
Cancer
.
2022
;
128
(
20
):
3691
-
3699
.
39.
Sordi
B
,
Vanderwert
F
,
Crupi
F
, et al
.
Disease correlates and clinical relevance of hereditary alpha-tryptasemia in patients with systemic mastocytosis
.
J Allergy Clin Immunol
.
2023
;
151
(
2
):
485
-
493.e411
.
40.
van Doormaal
JJ
,
van der Veer
E
,
van Voorst Vader
PC
, et al
.
Tryptase and histamine metabolites as diagnostic indicators of indolent systemic mastocytosis without skin lesions
.
Allergy
.
2012
;
67
(
5
):
683
-
690
.
41.
Lyons
JJ
,
Chovanec
J
,
O'Connell
MP
, et al
.
Heritable risk for severe anaphylaxis associated with increased alpha-tryptase-encoding germline copy number at TPSAB1
.
J Allergy Clin Immunol
.
2021
;
147
(
2
):
622
-
632
.
42.
Greiner
G
,
Sprinzl
B
,
Gorska
A
, et al
.
Hereditary alpha tryptasemia is a valid genetic biomarker for severe mediator-related symptoms in mastocytosis
.
Blood
.
2021
;
137
(
2
):
238
-
247
.
43.
Chollet
MB
,
Akin
C
.
Hereditary alpha tryptasemia is not associated with specific clinical phenotypes
.
J Allergy Clin Immunol
.
2022
;
149
(
2
):
728
-
735.e2
.
44.
Polivka
L
,
Madrange
M
,
Bulai-Livideanu
C
, et al
.
Pathophysiologic implications of elevated prevalence of hereditary alpha-tryptasemia in all mastocytosis subtypes
.
J Allergy Clin Immunol
.
2024
;
153
(
1
):
349
-
353.e4
.
45.
Gonzalez-de-Olano
D
,
Navarro-Navarro
P
,
Munoz-Gonzalez
JI
, et al
.
Clinical impact of the TPSAB1 genotype in mast cell diseases: a REMA study in a cohort of 959 individuals
.
Allergy
.
2024
;
79
(
3
):
711
-
723
.
46.
Valent
P
,
Horny
HP
,
Escribano
L
, et al
.
Diagnostic criteria and classification of mastocytosis: a consensus proposal
.
Leuk Res
.
2001
;
25
(
7
):
603
-
625
.
47.
Schwartz
LB
,
Metcalfe
DD
,
Miller
JS
,
Earl
H
,
Sullivan
T
.
Tryptase levels as an indicator of mast-cell activation in systemic anaphylaxis and mastocytosis
.
N Engl J Med
.
1987
;
316
(
26
):
1622
-
1626
.
48.
Sperr
WR
,
Jordan
JH
,
Baghestanian
M
, et al
.
Expression of mast cell tryptase by myeloblasts in a group of patients with acute myeloid leukemia
.
Blood
.
2001
;
98
(
7
):
2200
-
2209
.
49.
Sperr
WR
,
Stehberger
B
,
Wimazal
F
, et al
.
Serum tryptase measurements in patients with myelodysplastic syndromes
.
Leuk Lymphoma
.
2002
;
43
(
5
):
1097
-
1105
.
50.
Sperr
WR
,
El-Samahi
A
,
Kundi
M
, et al
.
Elevated tryptase levels selectively cluster in myeloid neoplasms: a novel diagnostic approach and screen marker in clinical haematology
.
Eur J Clin Invest
.
2009
;
39
(
10
):
914
-
923
.
51.
Klion
AD
,
Noel
P
,
Akin
C
, et al
.
Elevated serum tryptase levels identify a subset of patients with a myeloproliferative variant of idiopathic hypereosinophilic syndrome associated with tissue fibrosis, poor prognosis, and imatinib responsiveness
.
Blood
.
2003
;
101
(
12
):
4660
-
4666
.
52.
Lyons
JJ
,
Yu
X
,
Hughes
JD
, et al
.
Elevated basal serum tryptase identifies a multisystem disorder associated with increased TPSAB1 copy number
.
Nat Genet
.
2016
;
48
(
12
):
1564
-
1569
.
53.
Jendoubi
F
,
Shourick
J
,
Negretto
M
, et al
.
Cutaneous mastocytosis in adults with a serum tryptase level < 20 ng mL(-1) : why we should investigate further
.
Br J Dermatol
.
2021
;
185
(
2
):
453
-
455
.
54.
Alvarez-Twose
I
,
González-de-Olano
D
,
Sánchez-Muñoz
L
, et al
.
Validation of the REMA score for predicting mast cell clonality and systemic mastocytosis in patients with systemic mast cell activation symptoms
.
Int Arch Allergy Immunol
.
2012
;
157
(
3
):
275
-
280
.
55.
Sotlar
K
,
George
TI
,
Kluin
P
, et al
.
Standards of pathology in the diagnosis of systemic mastocytosis: recommendations of the EU-US Cooperative Group
.
J Allergy Clin Immunol Pract
.
2022
;
10
(
8
):
1986
-
1998.e2
.
56.
Escribano
L
,
Diaz-Agustin
B
,
López
A
, et al
.
Immunophenotypic analysis of mast cells in mastocytosis: when and how to do it. Proposals of the Spanish Network on Mastocytosis (REMA)
.
Cytometry B Clin Cytom
.
2004
;
58
(
1
):
1
-
8
.
57.
Sánchez-Muñoz
L
,
Morgado
JM
,
Álvarez-Twose
I
, et al
.
Diagnosis and classification of mastocytosis in non-specialized versus reference centres: a Spanish Network on Mastocytosis (REMA) study on 122 patients
.
Br J Haematol
.
2016
;
172
(
1
):
56
-
63
.
You do not currently have access to this content.
Sign in via your Institution